The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...

A clinical trial is launching to test the effectiveness of new tests that aim to detect genetic signatures of cancer in the ...

Fujirebio Diagnostics’ blood test for Alzheimer’s disease offers a less expensive and less invasive alternative compared to medical imaging and tests of cerebrospinal fluid. But competition ...

A first-of-its-kind blood test developed by Malvern-based Fujirebio Diagnostics to help diagnose Alzheimer’s disease has received clearance from the U.S. Food and Drug Administration, writes ...

Fujirebio submitted a regulatory filing with the FDA in September for its test. It is the first commercially available blood-based in vitro diagnostic test for assessing Alzheimer’s in the U.S.

But the Fujirebio Diagnostics test is the first one cleared by the FDA.“Blood-based biomarkers are reshaping how we identify and understand Alzheimer’s disease,” Carrillo said.

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

Quest Diagnostics to offer US FDA-approved Fujirebio blood test for Alzheimer's disease: Secaucus, New Jersey Friday, July 11, 2025, 14:00 Hrs [IST] Quest Diagnostics, a leader in ...